Multiscale imaging of the immune cell therapy biodistribution

Summary

Optimising therapeutic cell treatment is a challenge, especially with combination therapies and patient variability. The ability to study cell migration in a quantitative and non-invasive manner in vivo, of endogenous cancer-fighting immune cells (ICs) and administered therapeutic cells is essential for biomarker-driven and personalised clinical trials. Cenya BEACONs allow for multimodal, quantitative imaging of cell populations with quantitative 19F MRI, fluorescence, ultrasound, photoacoustics, PET and SPECT. Cenya’s GMP grade BEACONs consist of a PLGA shell and a PFCE multicore structure with Gd incorporated into the shell and can easily be used for a wide variety of therapeutic cells. The BEACONs are able to track cells over the course of multiple weeks and are cleared rapidly from dead cells.